ZimVie Inc. (NASDAQ:ZIMV - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $16.49, but opened at $19.52. ZimVie shares last traded at $18.70, with a volume of 156,458 shares changing hands.
Analysts Set New Price Targets
Several analysts recently weighed in on the stock. Barclays lifted their target price on shares of ZimVie from $13.00 to $16.00 and gave the company an "underweight" rating in a report on Tuesday, March 5th. JPMorgan Chase & Co. lifted their target price on shares of ZimVie from $10.00 to $16.00 and gave the company a "neutral" rating in a report on Wednesday, December 20th.
Check Out Our Latest Stock Report on ZIMV
ZimVie Trading Up 12.0 %
The company's 50 day simple moving average is $17.95 and its 200 day simple moving average is $13.66. The firm has a market cap of $500.17 million, a price-to-earnings ratio of -1.25 and a beta of 2.18. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.78 and a quick ratio of 2.32.
ZimVie (NASDAQ:ZIMV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.10 EPS for the quarter. The business had revenue of $113.07 million during the quarter. ZimVie had a negative net margin of 51.33% and a positive return on equity of 2.44%.
Institutional Investors Weigh In On ZimVie
Several institutional investors have recently modified their holdings of ZIMV. BlackRock Inc. purchased a new stake in shares of ZimVie during the 3rd quarter worth $32,184,000. Vanguard Group Inc. purchased a new stake in shares of ZimVie during the 3rd quarter worth $16,672,000. Balyasny Asset Management LLC purchased a new stake in shares of ZimVie during the 3rd quarter worth $11,555,000. Divisadero Street Capital Management LP purchased a new stake in shares of ZimVie during the 2nd quarter worth $11,230,000. Finally, State Street Corp purchased a new stake in shares of ZimVie during the 3rd quarter worth $9,358,000. 95.63% of the stock is owned by hedge funds and other institutional investors.
ZimVie Company Profile
(
Get Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Featured Stories
Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
